Harnessing and treating inflammatory and fibrotic diseases of today with a novel therapy of tomorrow
Aqualung Therapeutics Corporation, a Tucson, AZ- and Jupiter FL-based early stage biotech company with subsidiaries in Australia, is led by experienced life science executives and entrepreneurs with expertise in Inflammation and Fibrosis, Precision Medicine, Drug Development, Drug Manufacturing and Commercialization. They are committed to exploring eNAMPT as a key target and to applying the novel biologic therapeutic ALT-100 mAb to address the “unchecked inflammation and fibrosis” elicited by dysregulated innate immunity pathways in a variety of acute and chronic conditions with significant unmet therapeutic needs.
As an organization we are committed to finding novel targets in the treatment of inflammatory diseases. We are working collaboratively with the FDA to ensure both acute and chronic inflammatory diseases that have a significant unmet medical need receive the appropriate review. Where necessary we will be seeking priority review for specific indications based on epidemiology.